NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
NeuroSense to Host Investor Webinar on December 8, 2025
Business, regulatory and clinical updates will be provided